Search

Your search keyword '"Bavbek S"' showing total 4 results
Start Over Author "Bavbek S" Search Limiters Available in Library Collection Topic anaphylaxis
4 results on '"Bavbek S"'

1. Field sting reactions in patients receiving Hymenoptera venom immunotherapy: real-life experience.

Author

Sözener ZÇ, Kendirlinan R, Çerçi P, Ayd N Ö, Mungan D, Bavbek S, Demirel Y, Mısırl Gil Z, and Sin BA

Subjects
Humans, Animals, Adult, Middle Aged, Retrospective Studies, Wasp Venoms adverse effects, Desensitization, Immunologic adverse effects, Immunotherapy, Arthropod Venoms, Insect Bites and Stings therapy, Insect Bites and Stings etiology, Wasps, Hypersensitivity etiology, Hypersensitivity therapy, Anaphylaxis etiology
Abstract

Background: Hymenoptera stings can cause systemic allergic reactions (SARs) that are prevented by venom immunotherapy (VIT). Sting challenge tests or field stings are used to evaluate the outcome of VIT., Objective: The aim of the study was to investigate the consequences of field stings in patients during or after completion of VIT, and to identify patients at higher risk., Methods: Patients treated with VIT between 1995 and 2018 were retrospectively evaluated. Contacted patients were invited to the clinic and a questionnaire was conducted regarding the history of field stings., Results: A total of 115 patients (F/M: 45/70, mean age: 38.5 ± 12 years) treated with VIT were included; 74/115 were contacted and asked about field stings after VIT cessation. A history of 73 field stings was reported in 38 patients, 25 of whom were treated with honeybee venom and 13 with common wasp venom. Eighteen of the reactions were SARs [8 with honeybees (1 grade-I, 6 grade-II, 1 grade-III) and 10 with common wasps (1 grade-I, 5 grade-II, 4 grade-III)]. There was no association between the severity of index reactions and field stings with either the honeybee or common wasp. The median duration of VIT was longer in patients showing no reaction than in patients with an SAR. Of the 7 patients on ACE inhibitors or beta-blockers, 1 asthmatic patient developed grade-II SAR due to field stings in the first year of VIT., Conclusions: This study confirms that VIT lasting at least 3 years is effective in preventing SARs after field stings.

Published
2023
Full Text
View/download PDF

2. Successful Desensitization to Brentuximab After Anaphylactic Shock.

Author

Görgülü B, Toprak SK, and Bavbek S

Subjects
Adult, Anaphylaxis immunology, Antibodies, Monoclonal immunology, Brentuximab Vedotin, Desensitization, Immunologic methods, Humans, Immunoconjugates immunology, Male, Shock immunology, Anaphylaxis chemically induced, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal analysis, Immunoconjugates adverse effects, Shock chemically induced
Published
2018
Full Text
View/download PDF

3. Meloxicam-associated anaphylactic reaction.

Author

Bavbek S, Erkekol FO, Dursun B, and Misirligil Z

Subjects
Adult, Female, Humans, Meloxicam, Anaphylaxis chemically induced, Cyclooxygenase 2 Inhibitors adverse effects, Thiazines adverse effects, Thiazoles adverse effects
Abstract

Anaphylactic reaction to meloxicam has never been reported to date. We report 2 cases of meloxicam-induced anaphylactic reaction with no sensitivity to another selective cyclooxygenase 2 inhibitor. A thorough drug allergy work-up should be done before other cyclooxygenase inhibitors are prescribed.

Published
2006

4. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity

Author

Cortellini, G, Romano, A, Santucci, A, Barbaud, A, Bavbek, S, Bignardi, D, Blanca, M, Bonadonna, P, Costantino, M T, Laguna, J J, Lombardo, C, Losappio, L M, Makowska, J, Nakonechna, A, Quercia, O, Pastorello, E A, Patella, V, Terreehorst, I, Testi, S, Cernadas, J R, EAACI Drug Interest Group on Challenge and Desensitization Procedures with Aspirin in CAD, Dionicio Elera, J, Lippolis, D, Voltolini, S, Grosseto, D, Paediatric Pulmonology, Ear, Nose and Throat, and Amsterdam Cardiovascular Sciences

Subjects
Male, Acute coronary syndrome, Allergy, aspirin, medicine.medical_treatment, Immunology, Clinical Decision-Making, Myocardial Ischemia, challenge procedure, Comorbidity, 030204 cardiovascular system & hematology, nonsteroidal anti-inflammatory drugs hypersensitivity, Bronchospasm, Coronary artery disease, Drug Hypersensitivity, 03 medical and health sciences, 0302 clinical medicine, medicine, Immunology and Allergy, Humans, Desensitization (medicine), Aged, Aspirin, Angioedema, business.industry, Settore MED/09 - MEDICINA INTERNA, Anti-Inflammatory Agents, Non-Steroidal, Middle Aged, medicine.disease, desensitization procedure, Treatment Outcome, 030228 respiratory system, Desensitization, Immunologic, Anesthesia, Female, medicine.symptom, business, Anaphylaxis, Algorithms, medicine.drug
Abstract

Background Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with coronary artery disease. In such subjects, physicians have to choose the more appropriate procedure between challenge and desensitization. As the literature on this issue is sparse, the present study aims to establish in these subjects clinical criteria for eligibility for an ASA challenge and/or desensitization. Methods Collection and analysis of data on ASA challenges and desensitizations from 10 allergy centers, as well as consensus among the related physicians and an expert panel. Results Altogether, 310 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of non-immediate cutaneous eruptions, and 17 of bronchospasm related to ASA/NSAID intake. Specifically, 119 subjects had index reactions to ASA doses lower than 300 mg. Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent desensitizations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges. Overall, 163 subjects underwent challenges and 147 desensitizations; 86 of the latter had index reactions to ASA doses of 300 mg or less. Ten subjects reacted to challenges, 7 at doses up to 500 mg, 3 at a cumulative dose of 110 mg. The desensitization failure rate was 1.4%. Conclusions In patients with stable CIHD and histories of non-severe hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable. Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensitization. This article is protected by copyright. All rights reserved.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results